Case Le2-cv-00162-UNA DBocument4 File O¢/Od/22 Page dof 1 Pagsif #553
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`TRADEMARK
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are herebyadvised that a court action has been
`for the District of Delaware on the following
`
`filed in the U.S. District Court
`( Trademarks or
`[MW Patents.
`( [1 thepatent action involves 35 U.S.C. § 292.):
`
`ACERTA PHARMAB.V., ASTRAZENECA UK LIMITED,
`ASTRAZENECA PHARMACEUTICALSLP,
`ASTRAZENECAAB, and MERCK SHARP & DOHME
`B.V
`
`DEFENDANT
`
`CIPLA LIMITED and CIPLA USA, INC.
`
`
` Caee
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`CL] Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`OD Answer
`
`CD Cross Bill
`
`L] Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`2B
`
`e
`CSes
`po
`
`In the above—entitled case, the following decision has been rendered or judgementissued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Uponinitiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Uponfiling document adding patent(s), mail this copy to Director Copy 4—Casefile copy
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 1 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 1 of 891
`
`

`

`Case Le2-cv-00163-UNA Bocument4 Filed OGAeVe2 Page dof] Pagsid # 644
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`TRADEMARK
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are herebyadvised that a court action has been
`for the District of Delaware on the following
`
`filed in the U.S. District Court
`( Trademarks or
`[MW Patents.
`( [1 thepatent action involves 35 U.S.C. § 292.):
`
`ACERTA PHARMAB.V., ASTRAZENECA UK LIMITED,
`ASTRAZENECA PHARMACEUTICALSLP,
`ASTRAZENECAAB, and MERCK SHARP & DOHME
`B.V
`
`DEFENDANT
`
`MSN PHARMACEUTICALSINC.
`
`
` Caee
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`CL] Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`OD Answer
`
`CD Cross Bill
`
`L] Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`2B
`
`e
`CSes
`po
`
`In the above—entitled case, the following decision has been rendered or judgementissued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Uponinitiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Uponfiling document adding patent(s), mail this copy to Director Copy 4—Casefile copy
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 2 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 2 of 891
`
`

`

`Case De2-c-O0155-UNA Bocument4 Filed O¢/o2/e2 Rage dof 1 Pagsid #: 644
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`TRADEMARK
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are herebyadvised that a court action has been
`for the District of Delaware on the following
`
`filed in the U.S. District Court
`( Trademarks or
`[MW Patents.
`( [1 thepatent action involves 35 U.S.C. § 292.):
`
`ACERTA PHARMAB.V., ASTRAZENECA UK LIMITED,
`ASTRAZENECA PHARMACEUTICALSLP,
`ASTRAZENECAAB, and MERCK SHARP & DOHME
`B.V
`
`DEFENDANT
`
`NATCO PHARMA LIMITED and NATCO PHARMA, INC.
`
`
` Caee
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`CL] Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`OD Answer
`
`CD Cross Bill
`
`L] Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`2B
`
`e
`CSes
`po
`
`In the above—entitled case, the following decision has been rendered or judgementissued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Uponinitiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Uponfiling document adding patent(s), mail this copy to Director Copy 4—Casefile copy
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 3 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 3 of 891
`
`

`

`Case Le2-cv-O0154-UNA Document4 Filed O¢/o2/22 Page dof i Pagsif #553
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`TRADEMARK
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are herebyadvised that a court action has been
`for the District of Delaware on the following
`
`filed in the U.S. District Court
`( Trademarks or
`[MW Patents.
`( [1 thepatent action involves 35 U.S.C. § 292.):
`
`ACERTA PHARMAB.V., ASTRAZENECA UK LIMITED,
`ASTRAZENECA PHARMACEUTICALSLP,
`ASTRAZENECAAB, and MERCK SHARP & DOHME
`B.V
`
`DEFENDANT
`
`ALEMBIC PHARMACEUTICALS LIMITED
`and ALEMBIC PHARMACEUTICALS, INC.
`
`
` Caee
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`CL] Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`OD Answer
`
`CD Cross Bill
`
`L] Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`2B
`
`e
`CSes
`po
`
`In the above—entitled case, the following decision has been rendered or judgementissued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Uponinitiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Uponfiling document adding patent(s), mail this copy to Director Copy 4—Casefile copy
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 4 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 4 of 891
`
`

`

`Case Le2-cv-00164-UNA Document4 File O¢/od/22 Page dof 1 PagsiOf #643
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`TRADEMARK
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are herebyadvised that a court action has been
`for the District of Delaware on the following
`
`filed in the U.S. District Court
`( Trademarks or
`[MW Patents.
`( [1 thepatent action involves 35 U.S.C. § 292.):
`
`ACERTA PHARMAB.V., ASTRAZENECA UK LIMITED,
`ASTRAZENECA PHARMACEUTICALSLP,
`ASTRAZENECAAB, and MERCK SHARP & DOHME
`B.V
`
`DEFENDANT
`
`SANDOZ INC.
`
`
` Caee
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`CL] Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`OD Answer
`
`CD Cross Bill
`
`L] Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`2B
`
`e
`CSes
`po
`
`In the above—entitled case, the following decision has been rendered or judgementissued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Uponinitiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Uponfiling document adding patent(s), mail this copy to Director Copy 4—Casefile copy
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 5 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 5 of 891
`
`

`

`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`15/019,543
`
`ISSUE DATE
`
`09/12/2017
`
`PATENT NO.
`
`9758524
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`015332.1182-US02
`
`1984
`
`26853
`
`7590
`
`08/23/2017
`
`COVINGTON & BURLING, LLP
`Attn: Patent Docketing
`One CityCenter
`850 Tenth Street, NW
`Washington, DC 20001-4956
`
`The projected patent numberandissue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustmentis 0 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustmenton the front page.
`
`If a Continued Prosecution Application (CPA) wasfiled in the above-identified application, the filing date that
`determines Patent Term Adjustmentis the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEBsite (http://pair-uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM)at (571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEBsite http://pair.uspto.gov for additional applicants):
`
`‘Ljeerd A. Barf, Ravenstein, NETHERLANDS;
`Merck Sharp & Dohme B.V., Haarlem, NETHERLANDS;
`Christiaan Gerardus Johannes Maria Jans, Cuijk, NETHERLANDS;
`Adrianus Petrus Antonius de Man, Hurwenen, NETHERLANDS;
`Arthur A. Oubric, Wijchen, NETHERLANDS;
`IIans C. A. Raaiymakers, Lindhoven, NETIIERLANDS;
`Johannes Bernardus Maria Rewinkel, Berghem, NETHERLANDS;
`Jan Gerard Sterrenburg, Renkum, NETHERLANDS;
`Jacobus C. H. M. Wijkmans, Oss, NETHERLANDS;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`worksto encourage andfacilitate business investment. To learn more about why the USAis the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA. gov.
`
`IR103 (Rey. 10/09)
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 6 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 6 of 891
`
`

`

`PART B-FEE(S) TRANSMITTAL
`Complete and send this form, together with the applicable fee(s), to: Mail
`Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O, Box 1450
`Alexandria, Virginia 22314-1450)
`(S71)-273-2885
`or Fux
`
`
`and PUBLICATION FEE
`(if required}. Blocks | threugh 5 shauid be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE
`apprepriate. AU further correspondence including (he Patent, advance orders aad notification of maintenance fees will be mailed to the current correspondence address us
`indicated unless corrected belew or dircetcd otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS®
`for mainteaance fee notifications.
`CURRENTCORRESPONDENCE ADDRESS (Note Use Hack [lar say change of address)
`
`COVINGTON & BURLING LLP
`Atta: Patent Dockeling
`One CityCenter
`850 Teath Sueet, NW
`Washiagion, DC 20005-4956
`
`Note: A cettificate of mading can only be used for domestic
`mailings of the Feets) Transmittal. This certificate cannot be used
`for any other accompanying papers, Bach additional paper, such as
`an assignment or formal drawing, must have ils ows certificate of
`mailing ar transmission.
`Certificate of Mailing or Transmission
`] hereby certify that this Fee(s) Transmittal is being deposited with
`
`the United States Postal Service with sufficient postage for first
`chiss mail in an envelope addressed to the Mail Stop ISSUE FEE
`address abave, BFS-Webtransmitted, or facsimile transmitted Lo
`the USPTO (571) 273-2885, on the date indicated below,
`eresNar
`
`
`
`
`
`APPLICATION NG
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO
`
`CONFIRMATION NO
`
`15/019,543
`HT LE OFINVENTION:
`
`‘Tieerd A. Bari
`02/09/2016
`44IMIDAZOPY RIDAZIN-1-YL-BENZAMIDES AS BTR INFUBITORS
`
`15332,1182-USU2
`
`
`
`ENTITY STATUS|ISSUEFEE DUE|PUBLICATION FEE DUE|PREV. PAID ISSUER
`TOTAL FRE(S) DUE
`
`
`$960.00
`08/04/2017
`unoscounten|soonoo PP
`
`
`EXAMINER
`ART UNIT
`CLASS-SUBCLASS
`
`Golam M, Shameem
`1626
`
`(2)The name ofa single firm (havingasamembera=2. Einar Stole
`
`
`
`E. Change of correspondence address ot indication of "Fee
`2. Por printing on the patent fram page,list
`Address" (37CFR 1.363).
`
`(1) The names of up 10 3 registered patent attorneys=L. Covington & Burling LLP
`
`{or Change
`of
`Change
`oof
`correspondence
`address
`or agents OR, alternatively,
`
`Correspondence Address form PTO/SB/122) atlached,
`registered atlormey or agent) and the sames of up
`"Fee Address” indication (or "Fee Address” (ndication
`
`form PTO/SB/47; Rey 03-02 or more recent) attached. Use of
`ta2 registered aWOTAeY OF agent. Inonameiststed,
`4
`agatogy Wu
`no name will be printed
`a Customer Number is required.
`
`3. ASSIGNEE NAMEANDRESIDENCE DATA TO BE PRINTED ON THE PATENT(print of ype}
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assipnce is identified below, the dacument has beenfiled
`for recordation as set fork in 37 CFR 3.11. Completion of dhis form is NOTa substitute for filing an assignment.
`la. NAME OF ASSIGNEE
`(8) RESIDENCE: (CITY and STATE GR COUNTRY)
`Merck Shap & Dohme BY.
`Haarlem, Netherlands
`Please check the appropriate assignee categorics (will not be printedonthe patent}:
`[| Individual [x| Corporationorother privale geoup enlity [| Government
`4a. The following fee(s) are submitted:
`4b, Payment of Fees(s): (Please first reapply and previously paid fee shown above)
`Issue Fee
`[| A checkis enclosed
`[| Publication Fee (No small entity discount permiticd)
`[| Payment be eredil card. Form PTO-2038 is alached
`| Advance Order - # of Copies
`The director is hereby authorized to charge the required fee(s), any deficiency, or credits any
`overpayment, 10 Deposit Account Number=50-0740=~(enclose an extra copy of this form)
`5, Change of Entity Status (fromstatus indicated above)
`NOTE: Absent a vulid certification of Micro EntityStatus (see forms PTO/SI/15A and 158), issue
`Applicant certifying microentity stalus, See 37 CFR 1.29)
`fee payment in the micro entity amount will not be aecepted af the cisk of application abandonment,
`NOTE: if the application was previously under micro entity status, checking this hex will be taken
`[| Applicant asserting stall entity status, Sce 37 CFR 1.27
`to be a notification of less of entitlement to mictocality status.
`NOTE: Checking this box will be taken to be notification of loss of eatilement to small of micro
`[| Applicant changing to regular undiscounled fee status.
`entily states, as applicable.
`NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33, See 37 CFR 1.4 for signature requirements and certifications.
`
`Authorized Signatare a Bate
`
`Typed or printed aame
`
`Melody H. Wu
`
`August 3, 2017
`
`32,376
`
`Registration No,
`
`PTOL-85 Part B (06-17) Approved for ase through 1/31/2020
`
`OMB0651-0033
`
`U.S, Patent and Trademark Office: U.S. DEPARTMENT GP COMMERCE
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 7 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 7 of 891
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`15019543
`
`09-Feb-2016
`
`Title of Invention:
`
`4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
`
`First NamedInventor/Applicant Name:
`
`Tjeerd A. Barf
`
`Andrea Reister/Jenn Augsburger
`
`Attorney Docket Number:
`
`015332.1182-US02
`
`Filed as Large Entity
`
`Filing Fees for Utility under 35 USC 111(a)
`
`
`
`
`
`
`
`UTILITY APPL ISSUE FEE
`
`Sub-Total in
`Fee Code Quantity AmountDescription USD(S)
`
`
`
`Basic Filing:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 8 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 8 of 891
`
`

`

`Extension-of-Time:
`
`Total in USD ($)
`
`Miscellaneous:
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 9 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 9 of 891
`
`

`

`
`
`Electronic AcknowledgementReceipt
`
`a a
`
`eons
`
`Title of Invention:
`
`4-IMIDAZOPYRIDAZIN- 1-YL-BENZAMIDESAS BTK INHIBITORS
`
`First Named Inventor/Applicant Name:
`
`Tjeerd A. Barf
`
`Customer Number:
`
`26853be
`eo
`
`Utility under 35 USC 111{a)
`Application Type:
`
`
`Paymentinformation:
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`
`
`[Beposkaccune——SSSSCSC*dSS
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 10 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 10 of 891
`
`

`

`
`
`Pages
`Multi
`File Size(Bytes)/
`Document Description
`Document
`
`
`
`Number Message Digest|Part /.zip|P (if appl.)
`
`
`
`—
`
`DocumentDescription
`
`Transmittal Letter
`
`Issue Fee Payment (PTO-85B)
`
`
`
`Information:
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`09ddbf106cdd23817e31 13f65/4d9b1fll}
`
`Warnings:
`Information:
`
`Total Files Size (in bytes)
`
`114621
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable.It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new applicationis being filed and the application includes the necessary componentsfor a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shownonthis
`Acknowledgement Receiptwill establish thefiling date of the application.
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptanceof the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`NewInternational Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary componentsfor
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`andof the International Filing Date (Form PCT/RO/105)will be issued in due course, subject to prescriptions concerning
`national security, and the date shown onthis Acknowledgement Receiptwill establish the international filing date of
`the application.
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 11 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 11 of 891
`
`

`

`Docket No.: 015332,1182-US02
`(PATENT)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`InrePatentApplicationcfs
`Tjeerd A. Barf et al.
`
`Application No,; 15/019,543
`
`Filed: February 9, 2016
`
`Allowed: May 4, 2017
`
`Confirmation No.: 1984
`
`Art Unit: 1626
`
`For: 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES—Examiner: Golam M. Shameem
`AS BTK INHIBITORS
`
`TRANSMITTAL LETTER
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Dear Sir:
`
`Enclosed are the following items for filing in connection with the above-referenced
`
`Patent Application:
`
`1.
`
`Fee(s) Transmittal.
`
`Please charge our Deposit Account No. 50-0740 in the amount of $960.00in payment of
`
`the required fee. The Directoris hereby authorized to charge any deficiency in the fees filed,
`
`asserted to be filed, or that should have been filed herewith (or with any paper hereafterfiled in this
`
`application bythis firm) to our Deposit Account No. 50-0740, under Docket No. 015332.1182-
`
`US02.
`
`It is not believed that extensions of time or fees for net addition of claims are required
`
`beyond those that may otherwise be provided for in documents accompanying this paper. However,
`
`if additional extensions of time are necessary to prevent abandonmentof this application, then such
`
`extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor
`
`DC: 6485703-1
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 12 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 12 of 891
`
`

`

`Application No.: 15/019,543
`
`2
`
`Docket No.: 015332.1182-US02
`
`(including fees for net addition of claims) are hereby authorized to be charged to our Deposit
`
`Account No. 50-0740.
`
`Dated: August 3, 2017
`
`Respectfully submitted,
`
`
`
`Registration No.: 47,272
`Meledy H. Wu
`Registration No.: 52,376
`COVINGTON & BURLING LLP
`One CityCenter
`850 Tenth Street, NW
`Washington, DC 20001-4956
`(202) 662-6000
`Attorneys for Applicant
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 13 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 13 of 891
`
`

`

`
`
`UNITED StaTreS PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and ‘Trademark Office
`Address: COMMTSSIONER, FOR PATENTS
`P.C. Box 1450
`Alexandria, Virgnia 22313-1450
`Wwww.uspto.gov
`
`APPLICATION
`FILINGor
`GRP AR’
`
`NUMBER
`371(¢) DATE
`UNI
`FIL FEE REC'D
`[TOT CLAIMS§IND CLAIMS
`ATTY.DOCKET.NO
`015332.1182-US02 CONFIRMATION NO.“1984
`15/019,543
`02/09/2016
`1626
`1740
`
`26853
`COVINGTON & BURLING, LLP
`Attn: Patent Docketing
`One CityCenter
`850 Tenth Street, NW
`Washington, DC 20001-4956
`
`CORRECTED FILING RECEIPT
`LOU
`
`Date Mailed: 06/06/2017
`
`Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination
`in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the
`application mustinclude the following identification information: the U.S. APPLICATION NUMBER, FILING DATE,
`NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.
`Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please
`submit a written request for a Filing Receipt Correction. Please provide a copy ofthis Filing Receipt with the
`changesnotedthereon. If you received a "Notice to File Missing Parts" for this application, please submit
`any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processesthe reply
`to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections
`
`Inventor(s)
`
`Tjeerd A. Barf, Ravenstein, NETHERLANDS;
`Christiaan Gerardus Johannes Maria Jans, Cuijk, NETHERLANDS;
`Adrianus Petrus Antonius de Man, Hurwenen, NETHERLANDS;
`Arthur A. Oubrie, Wijchen, NETHERLANDS;
`Hans C. A. Raaijmakers, Eindhoven, NETHERLANDS;
`Johannes Bernardus Maria Rewinkel, Berghem, NETHERLANDS;
`Jan Gerard Sterrenburg, Renkum, NETHERLANDS;
`Jacobus C. H. M. Wijkmans, Oss, NETHERLANDS;
`
`Applicant(s)
`
`Merck Sharp & Dohme B.V., Haarlem, NETHERLANDS;
`
`Powerof Attorney: None
`
`Domestic Priority data as claimed by applicant
`This application is a DIV of 14/233,418 01/17/2014 PAT 9290504
`whichis a 371 of PGT/EP2012/063552 07/11/2012
`which claims benefit of 61/509,397 07/19/2011
`
`Foreign Applications (You maybe eligible to benefit from the Patent Prosecution Highway program at the
`USPTO. Please see http://www.uspto.gov for more information.)
`EUROPEAN PATENTOFFICE (EPO) 11174578.2 07/19/2011
`
`Permission to Access Application via Priority Document Exchange: No
`
`Permission to Access Search Results: No
`
`page 1 of 4
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 14 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 14 of 891
`
`

`

`Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as
`appropriate.
`
`Request to Retrieve - This application either claims priority to one or more applications filed in an intellectual
`property Office that participates in the Priority Document Exchange (PDX) program or contains a proper Request to
`Retrieve Electronic Priority Application(s) (PTO/SB/38or its equivalent). Consequently, the USPTO will attempt
`to electronically retrieve these priority documents.
`
`If Required, Foreign Filing License Granted: 06/05/2017
`The country code and number of your priority application, to be used for filing abroad under the Paris Convention,
`is US 15/019,543
`Projected Publication Date: Not Applicable
`Non-Publication Request: No
`Early Publication Request: No
`Title
`
`4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
`
`Preliminary Class
`544
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No
`
`PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES
`
`Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no
`effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent
`in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international
`application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same
`effect as a regular national patent application in each PCT-member country. The PCT process simplifies thefiling
`of patent applications on the same invention in member countries, but does not result in a grant of "an international
`patent" and doesnoteliminate the need of applicants to file additional documents and fees in countries where patent
`protection is desired.
`
`Almost every country has its own patent law, and a person desiring a patent in a particular country must make an
`application for patent in that country in accordancewith its particular laws. Since the laws of many countries differ
`in various respects from the patent law of the United States, applicants are advised to seek guidance from specific
`foreign countries to ensure that patent rights are not lost prematurely.
`
`Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must
`issue a license before applicants can apply for a patent in a foreign country. Thefiling of a U.S. patent application
`serves as a request for a foreign filing license. The application's filing receipt contains further information and
`guidanceasto the status of applicant's license for foreign filing.
`
`Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents” (specifically, the
`section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlinesfor filing foreign
`patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it
`can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.
`
`page 2 of 4
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 15 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 15 of 891
`
`

`

`For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish
`to consult the U.S. Government website, http:/Avww.stopfakes.gov. Part of a Department of Commerceinitiative,
`this website includes self-help "toolkits" giving innovators guidance on howto protectintellectual property in specific
`countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may
`call the U.S. Governmenthotline at 1-866-999-HALT (1-866-999-4258).
`
`LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`if the phrase "IF REQUIRED, FOREIGN FILING
`The applicant has been granted a license under 35 U.S.C. 184,
`LICENSE GRANTED"followed by a date appears on this form. Such licenses are issuedin all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope andlimitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be usedat any time onor after the effective date thereof unless
`itis revoked. This license is automatically transferred to any related applications(s)filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grantof a license does not in any waylessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselvesof current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Departmentof
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted atthis time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOTappear on this form. Applicant maystill petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from thefiling date of the application. If 6 months has lapsed
`from thefiling date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee mayforeign file the application pursuant to 37 CFR 5.15(b).
`
`
`SelectUSA
`
`The United States represents the largest, most dynamic marketplacein the world and is an unparalleled location for
`businessinvestment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to
`promoteandfacilitate business investment. SelectUSA provides information assistanceto the international investor
`
`page 3 of 4
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 16 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 16 of 891
`
`

`

`community; serves as an ombudsmanfor existing and potential investors; advocates on behalf of U.S. cities, states,
`and regions competing for global investment; and counsels U.S. economic developmentorganizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology, manufacture products, deliver services, and grow your business, visit http:/Awww.SelectUSA.govor call
`+1-202-482-6800.
`
`page 4 of 4
`
`SANDOZINC.
`
`IPR2023-00478
`
`Ex. 1023, p. 17 of 891
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1023, p. 17 of 891
`
`

`

`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`NOTICE OF ALLOWANCEAND FEE(S) DUE
`
`2688
`
`1350
`
`esiwa0i7
`
`COVINGTON & BURLING, LLP
`Attn: Patent Docketing
`One CityCenter
`850 Tenth Strect, NW
`Washington, DC 20001-4956
`
`SHAMEEM, GOLAM M
`
`ART UNIT
`6
`
`PAPER NUMBER
`
`DATE MAILED: 05/04/2017
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEYDOCKET NO.
`
`CONFIRMATION NO.
`
`015332.1182-US02
`Tjeerd A. Barf
`02/09/2016
`15/019,543
`TITLE OF INVENTION: 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
`
`1984
`
`
`
`
`
`
`
`
`
`
`
`APPIN. TYPR PUBLICATION FER DUP.|PREV. PAID ISSUE FRRENTITY STATUS ISSTTF FRE DUR TOTAT. FER(S) DUE DATE DUR
`
`
`
`$960
`
`08/04/2017
`
`nonprovisional
`
`UNDISCOUNTED
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCEAS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. TIS NOTICE OF ALLOWANCEIS NOT A GRANT OF PATENT RIGIITS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CER 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED.
`SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THEISSUE FEE NOW
`DUE.
`
`HOW TO REPLY TO THIS NOTICE:
`
`I. Review the ENTITY STATUSshownabove.If the ENTITY STATUSis shown as SMALL or MICRO,verify whether entitlement to that
`entity status sull applies.
`If the ENTITY STATUS is the same as shownabove, pay the TOTAL FEE(S) DUE shownabove.
`If the ENTITY STATUS is changed from that shown above, on PART B - FER(S) TRANSMITTAL, complete section numbe